2025
Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil
Puga M, de Oliveira R, da Silva P, Charu V, Hedlin H, Lu D, Zhang A, Shaw B, Rosser J, Seidman J, Carter A, Qamar F, Luby S, Garrett D, Croda J. Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil. The Lancet Regional Health - Americas 2025, 44: 101031. PMID: 40083966, PMCID: PMC11904515, DOI: 10.1016/j.lana.2025.101031.Peer-Reviewed Original ResearchDose of BNT162b2Fractionated dosesNon-inferiorityNon-inferiority thresholdSeroresponse ratesDouble-blindBooster vaccinationAdverse eventsSystemic adverse eventsPhase IV clinical trialBaseline antibody levelsIV clinical trialDose of COVID-19 vaccineDose of vaccineNon-inferiority studyReduced side effectsAdministering booster vaccinationResource-limited settingsBinding IgG antibodiesImmunocompetent adultsStudy vaccineDose boosterTreatment armsParallel-groupBooster dose
2024
Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis
Murray T, Stanley G, Koff J. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Infectious Disease Clinics Of North America 2024, 38: 149-162. PMID: 38280761, DOI: 10.1016/j.idc.2023.12.002.Peer-Reviewed Original ResearchConceptsMultidrug-resistant organismsCystic fibrosis transmembrane conductance regulatorCystic fibrosisBeta-lactam/beta-lactamase combinationDevelopment of inhaled formulationsMethicillin-resistant Staphylococcus aureusTherapeutic approachesMultidrug-resistant organism infectionSystemic adverse eventsMultidrug-resistant infectionsTransmembrane conductance regulatorRespiratory tract infectionsCystic fibrosis patientsGram-negative organismsInnovative therapeutic approachesPulmonary infectionTract infectionsConductance regulatorBurkholderia sp.Multidrug resistanceAdverse eventsTreatment optionsAntibiotic resistanceFibrosis patientsOptimal dose
2022
Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis
Murray T, Stanley G, Koff J. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Clinics In Chest Medicine 2022, 43: 667-676. PMID: 36344073, DOI: 10.1016/j.ccm.2022.06.008.Peer-Reviewed Original ResearchConceptsMultidrug-resistant organismsCystic fibrosisTherapeutic approachesNontuberculous mycobacteriaCystic fibrosis transmembrane conductance regulator (CFTR) dysfunctionSystemic adverse eventsRespiratory tract infectionsMethicillin-resistant Staphylococcus aureusAdditional clinical trialsNew treatment optionsPharmacokinetics/pharmacodynamicsInnovative therapeutic approachesMultidrug-resistant infectionsMDRO infectionAdverse eventsPulmonary infectionTract infectionsOptimal dosingTreatment optionsClinical trialsNew therapiesNegative organismsInfectionAntibiotic resistancePatients
2018
Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice
Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice. Ophthalmology 2018, 126: 1007-1015. PMID: 30292542, DOI: 10.1016/j.ophtha.2018.09.040.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaRoutine clinical practiceSystemic serious adverse eventsMacular laserMajor bleedingCerebrovascular diseaseMyocardial infarctionClinical practiceCause hospitalizationAdverse eventsHazard ratioIntravitreal corticosteroidsAnti-VEGFMacular edemaDME treatmentTreatment of DMEIntravitreal anti-VEGF therapyCox proportional hazards regressionAnti-VEGF pharmacotherapySystemic safety profileCorticosteroid-treated patientsRetrospective cohort studySerious adverse eventsSystemic adverse eventsMacular laser photocoagulation
1999
Therapeutic Angiogenesis Using Endocardial Approach to Administration: Techniques and Results.
Garcia L, Baim D, Post M, Simons M, Laham R. Therapeutic Angiogenesis Using Endocardial Approach to Administration: Techniques and Results. Current Interventional Cardiology Reports 1999, 1: 222-227. PMID: 11096628.Peer-Reviewed Original ResearchTherapeutic angiogenesisClinical trialsClinical studiesPreclinical studiesSurgical accessSerious systemic adverse eventsSystemic adverse eventsIschemic heart diseaseMost clinical trialsChronic myocardial ischemiaThree-dimensional navigation systemMost preclinical studiesDelivery strategiesAngiogenic growth factorsAdverse eventsLocal therapyGeneral anesthesiaMyocardial ischemiaHeart diseaseFluoroscopic guidanceClinical usefulnessEndocardial approachSystemic recirculationAnimal modelsDelivery catheter
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply